Research
Hormonal
Pioglitazone and GLP-1 receptor agonists are promising treatments for NAFLD that also benefit the vasculature.
Clinicians may consider these medications for managing NAFLD and associated cardiovascular risks.
StrongSupportsmedium confidence
Of the currently tested drugs for treating NAFLD that also benefit the vasculature, pioglitazone and GLP-1 receptor agonists are the most promising.
Why this rating
The claim is based on a narrative review of existing literature.
Source
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
Christopher D. Byrne et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14484
reviewCited 113×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →